Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis

FASEB Journal

Volumn 24, Issue 8, 2010, Pages 2680-2688

  Costa, Barbara ^a,b   Dettori, Daniela ^a,b,c   Lorenzato, Annalisa ^a,b   Bardella, Chiara ^a,b   Coltella, Nadia ^a,b   Martino, Cosimo ^a,b   Cammarata, Cristina ^a,b   Carmeliet, Peter ^c,d   Olivero, Martina ^a,b   Di Renzo, Maria Flavia ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Hypoxia inducible factor; Mitochondrial tumor suppressors; Tyrosine kinase oncogenes

Indexed keywords

FUMARATE HYDRATASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RAS PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL MOTILITY; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; FEMALE; FIBROBLAST; GENE ACTIVATION; GENE EXPRESSION; GENE INACTIVATION; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOUSE; MOUSE EMBRYO; NONHUMAN; ONCOGENE; PHENOTYPE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FIBROBLASTS; FUMARATE HYDRATASE; HEPATOCYTE GROWTH FACTOR; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; TUMOR SUPPRESSOR PROTEINS;

EID: 77955815630     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.09-146928     Document Type: Article

References (52)

1. Tomlinson, I. P., Alam, N. A., Rowan, A. J., Barclay, E., Jaeger, E. E., Kelsell, D., Leigh, I., Gorman, P., Lamlum, H., Rahman, S., Roylance, R. R., Olpin, S., Bevan, S., Barker, K., Hearle, N., Houlston, R. S., Kiuru, M., Lehtonen, R., Karhu, A., Vilkki, S., Laiho, P., Eklund, C., Vierimaa, O., Aittomaki, K., Hietala, M., Sistonen, P., Paetau, A., Salovaara, R., Herva, R., Launonen, V., and Aaltonen, L. A. (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406-410
2. Toro, J. R., Nickerson, M. L., Wei, M. H., Warren, M. B., Glenn, G. M., Turner, M. L., Stewart, L., Duray, P., Tourre, O., Sharma, N., Choyke, P., Stratton, P., Merino, M., Walther, M. M., Linehan, W. M., Schmidt, L. S., and Zbar, B. (2003) Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am. J. Hum. Genet. 73, 95-106
3. Gottlieb, E., and Tomlinson, I. P. (2005) Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 5, 857-866
4. Pollard, P., Wortham, N., Barclay, E., Alam, A., Elia, G., Manek, S., Poulsom, R., and Tomlinson, I. (2005) Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J. Pathol. 205, 41-49
5. Pollard, P. J., Spencer-Dene, B., Shukla, D., Howarth, K., Nye, E., El-Bahrawy, M., Deheragoda, M., Joannou, M., McDonald, S., Martin, A., Igarashi, P., Varsani-Brown, S., Rosewell, I., Poulsom, R., Maxwell, P., Stamp, G. W., and Tomlinson, I. P. (2007) Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 11, 311-319
6. Pollard, P. J., Briere, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., Hargreaves, I. P., Heales, S. J., Chung, Y. L., Griffiths, J. R., Dalgleish, A., McGrath, J. A., Gleeson, M. J., Hodgson, S. V., Poulsom, R., Rustin, P., and Tomlinson, I. P. (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231-2239
7. Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y. L., Merino, M., Trepel, J., Zbar, B., Toro, J., Ratcliffe, P. J., Linehan, W. M., and Neckers, L. (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-153
8. Kaelin, W. G., Jr. (2007) The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13, 680s-684s.
9. Baysal, B. E. (2003) On the association of succinate dehydrogenase mutations with hereditary paraganglioma. Trends Endocrinol. Metab. 14, 453-459
10. Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., Chidambaram, A., Bergerheim, U. R., Feltis, J. T., Casadevall, C., Zamarron, A., Bernues, M., Richard, S., Lips, C. J., Walther, M. M., Tsui, L. C., Geil, L., Orcutt, M. L., Stackhouse, T., and Zbar, B. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat. Genet. 16, 68-73
11. Natali, P. G., Prat, M., Nicotra, M. R., Bigotti, A., Olivero, M., Comoglio, P. M., and Di Renzo, M. F. (1996) Overexpression of the met/HGF receptor in renal cell carcinomas. Int. J. Cancer 69, 212-217
12. Inoue, K., Karashima, T., Chikazawa, M., Iiyama, T., Yoshikawa, C., Furihata, M., Ohtsuki, Y., and Shuin, T. (1998) Overexpression of c-met proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth. Virchows Arch. 433, 511-515
13. Yamauchi, M., Kataoka, H., Itoh, H., Seguchi, T., Hasui, Y., and Osada, Y. (2004) Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma. J. Urol. 171, 890-896
14. Miyata, Y., Kanetake, H., and Kanda, S. (2006) Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin. Cancer Res. 12, 4876-4881
15. Trusolino, L., and Comoglio, P. M. (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer 2, 289-300
16. Birchmeier, C., Birchmeier, W., Gherardi, E., and Vande Woude, G. F. (2003) Met, metastasis, motility and more. Nat. Rev. Mol. Cell. Biol. 4, 915-925
17. Corso, S., Migliore, C., Ghiso, E., De Rosa, G., Comoglio, P. M., and Giordano, S. (2008) Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 27, 684-693
18. Knudsen, B. S., and Vande Woude, G. (2008) Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev. 18, 87-96
19. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., and Comoglio, P. M. (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protoon-cogene. Cancer Cell 3, 347-361
20. Ide, T., Kitajima, Y., Miyoshi, A., Ohtsuka, T., Mitsuno, M., Ohtaka, K., Koga, Y., and Miyazaki, K. (2006) Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/ c-Met pathway. Int. J. Cancer 119, 2750-2759
21. Scarpino, S., Cancellario d'Alena, F., Di Napoli, A., Pasquini, A., Marzullo, A., and Ruco, L. P. (2004) Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J. Pathol. 202, 352-358
22. Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C. J., Ratcliffe, P., Moons, L., Jain, R. K., Collen, D., and Keshert, E. (1998) Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490
23. Lorenzato, A., Olivero, M., Perro, M., Briere, J. J., Rustin, P., and Di Renzo, M. F. (2008) A cancer-predisposing "hot spot" mutation of the fumarase gene creates a dominant negative protein. Int. J. Cancer 122, 947-951
24. Amendola, M., Venneri, M. A., Biffi, A., Vigna, E., and Naldini, L. (2005) Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat. Biotechnol. 23, 108-116
25. Barbacid, M. (1987) ras genes. Annu. Rev. Biochem. 56, 779-827
26. Lorenzato, A., Olivero, M., Patane, S., Rosso, E., Oliaro, A., Comoglio, P. M., and Di Renzo, M. F. (2002) Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res. 62, 7025-7030
27. Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., Autiero, M., Wyns, S., Plaisance, S., Moons, L., van Rooijen, N., Giacca, M., Stassen, J. M., Dewerchin, M., Collen, D., and Carmeliet, P. (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463-475
28. Sudarshan, S., Sourbier, C., Kong, H. S., Block, K., Romero, V. V., Yang, Y., Galindo, C., Mollapour, M., Scroggins, B., Goode, N., Lee, M. J., Gourlay, C. W., Trepel, J., Linehan, W. M., Neckers, L., Xie, H., Valera, V. A., Merino, M. J., Amato, A. M., Signoretti, S., Linehan, W. M., Sukhatme, V. P., and Seth, P. (2009) Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and HIF-1α stabilization by glucose-dependent generation of reactive oxygen species LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol. Cell Biol. 26, 26
29. Briere, J. J., Favier, J., Benit, P., El Ghouzzi, V., Lorenzato, A., Rabier, D., Di Renzo, M. F., Gimenez-Roqueplo, A. P., and Rustin, P. (2005) Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum. Mol. Genet. 14, 3263-3269
30. Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7, 77-85
31. Bramwell, V. H., Tuck, A. B., Wilson, S. M., Stitt, L. W., Cherian, A. K., Rorke, S. C., Al-Katib, W., Postenka, C. O., and Chambers, A. F. (2005) Expression of osteopontin and HGF/met in adult soft tissue tumors. Cancer Biol. Ther. 4, 1336-1341
32. Scotlandi, K., Baldini, N., Oliviero, M., Di Renzo, M. F., Martano, M., Serra, M., Manara, M. C., Comoglio, P. M., and Ferracini, R. (1996) Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am. J. Pathol. 149, 1209-1219
33. Gherardi, E., and Stoker, M. (1990) Hepatocytes and scatter factor [letter]. Nature 346, 228
34. Rong, S., Donehower, L. A., Hansen, M. F., Strong, L., Tainsky, M., Jeffers, M., Resau, J. H., Hudson, E., Tsarfaty, I., and Vande Woude, G. F. (1995) Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res. 55, 1963-1970
35. Michieli, P., Mazzone, M., Basilico, C., Cavassa, S., Sottile, A., Naldini, L., and Comoglio, P. M. (2004) Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6, 61-73
36. Christensen, J. G., Schreck, R., Burrows, J., Kuruganti, P., Chan, E., Le, P., Chen, J., Wang, X., Ruslim, L., Blake, R., Lipson, K. E., Ramphal, J., Do, S., Cui, J. J., Cherrington, J. M., and Mendel, D. B. (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 63, 7345-7355
37. Yang, Y., Wislez, M., Fujimoto, N., Prudkin, L., Izzo, J. G., Uno, F., Ji, L., Hanna, A. E., Langley, R. R., Liu, D., Johnson, F. M., Wistuba, I., and Kurie, J. M. (2008) A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol. Cancer Ther. 7, 952-960
38. Semenza, G. L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732
39. Tacchini, L., De Ponti, C., Matteucci, E., Follis, R., and Desiderio, M. A. (2004) Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis 25, 2089-2100
40. Kataoka, H., Miyata, S., Uchinokura, S., and Itoh, H. (2003) Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev. 22, 223-236
41. Blum, R., Jacob-Hirsch, J., Amariglio, N., Rechavi, G., and Kloog, Y. (2005) Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res. 65, 999-1006
42. Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhofer, N., Kong, C., Le, Q. T., Chi, J. T., Jeffrey, S. S., and Giaccia, A. J. (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222-1226
43. Li, W., Li, Y., Guan, S., Fan, J., Cheng, C. F., Bright, A. M., Chinn, C., Chen, M., and Woodley, D. T. (2007) Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. EMBO J. 26, 1221-1233
44. Denko, N. C. (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 8, 705-713
45. Bedogni, B., Welford, S. M., Cassarino, D. S., Nickoloff, B. J., Giaccia, A. J., and Powell, M. B. (2005) The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 8, 443-454
46. Rohwer, N., Welzel, M., Daskalow, K., Pfander, D., Wiedenmann, B., Detjen, K., and Cramer, T. (2008) Hypoxia-inducible factor 1alpha mediates anoikis resistance via suppression of alpha5 integrin. Cancer Res. 68, 10113-10120
47. Ryan, H. E., Poloni, M., McNulty, W., Elson, D., Gassmann, M., Arbeit, J. M., and Johnson, R. S. (2000) Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60, 4010-4015
48. Long, I. S., Han, K., Li, M., Shirasawa, S., Sasazuki, T., Johnston, M., and Tsao, M. S. (2003) Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo. Mol. Cancer Res. 1, 393-401
49. Bertotti, A., and Comoglio, P. M. (2003) Tyrosine kinase signal specificity: lessons from the HGF receptor. Trends Biochem. Sci. 28, 527-533
50. Koski, T. A., Lehtonen, H. J., Jee, K. J., Ninomiya, S., Joosse, S. A., Vahteristo, P., Kiuru, M., Karhu, A., Sammalkorpi, H., Vanharanta, S., Lehtonen, R., Edgren, H., Nederlof, P. M., Hietala, M., Aittomaki, K., Herva, R., Knuutila, S., Aaltonen, L. A., and Launonen, V. (2009) Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer. Genes Chromosomes Cancer 16, 16
51. Bardos, J. I., and Ashcroft, M. (2004) Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 26, 262-269
52. Comoglio, P. M., Giordano, S., and Trusolino, L. (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7, 504-516